Loading...
XSHG600085
Market cap7.82bUSD
Dec 25, Last price  
41.60CNY
1D
-0.29%
1Q
24.45%
Jan 2017
32.63%
Name

Beijing Tongrentang Co Ltd

Chart & Performance

D1W1MN
XSHG:600085 chart
P/E
34.19
P/S
3.19
EPS
1.22
Div Yield, %
0.85%
Shrs. gr., 5y
—
Rev. gr., 5y
4.68%
Revenues
17.86b
+16.19%
2,445,252,1402,605,732,4362,396,505,1762,702,850,9392,939,049,5113,250,219,8843,824,446,1416,108,383,7117,504,031,9778,714,647,4019,685,867,52210,808,761,22912,090,740,12213,375,966,34414,208,636,44613,277,123,19912,825,879,05014,603,100,73915,372,423,36317,860,891,456
Net income
1.67b
-24.12%
286,780,097301,231,159156,021,181232,891,142258,946,471285,610,659343,233,607438,066,654570,056,218656,013,728763,669,171875,179,501933,165,3911,017,381,5491,134,283,8471,561,601,3281,616,363,3051,890,760,4592,199,390,8111,668,834,509
CFO
1.87b
-39.58%
415,822,179191,538,984384,559,921121,020,805422,789,931627,689,915492,043,803544,905,320873,968,414676,398,667696,013,987832,472,8451,045,766,4821,448,915,1621,928,378,9942,273,710,5392,174,631,6633,426,414,5633,094,296,2841,869,491,851
Dividend
Oct 10, 20240.5 CNY/sh
Earnings
Jun 13, 2025

Profile

Beijing Tongrentang Co., Ltd engages in the scientific research, production, sale, and distribution of Chinese medicines in China and internationally. It covers product formulations, such as pills, powders, wines and capsules, oral liquids, and dripping pills with the original powder preparation in the areas of cardiovascular, cerebrovascular, and gynecological diseases, as well as anti-depressive new drugs. The company sells its products under the brand names of Angong Niuhuang series, Tongren Niuhuang Qingxin series, Tongren Dahuoluo series, Yufeng Ningxin dripping pills, Hemiplegia recovery pills, etc. The company is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.
URL
https://gf.tongrentang.com/
IPO date
Jun 25, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
17,860,891
16.19%
15,372,423
5.27%
14,603,101
13.86%
Cost of revenue
11,253,532
11,444,700
10,880,170
Unusual Expense (Income)
NOPBT
6,607,360
3,927,724
3,722,931
NOPBT Margin
36.99%
25.55%
25.49%
Operating Taxes
497,429
517,547
436,514
Tax Rate
7.53%
13.18%
11.73%
NOPAT
6,109,931
3,410,177
3,286,416
Net income
1,668,835
-24.12%
2,199,391
16.32%
1,890,760
16.98%
Dividends
(483,095)
(397,726)
(370,297)
Dividend yield
0.66%
0.65%
0.60%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
93,025
795,422
1,354,728
Long-term debt
3,561,244
2,943,340
3,018,138
Deferred revenue
157,568
153,956
198,241
Other long-term liabilities
167,097
9,475
10,218
Net debt
(8,503,430)
(7,913,355)
(5,723,289)
Cash flow
Cash from operating activities
1,869,492
3,094,296
3,426,415
CAPEX
(324,515)
Cash from investing activities
(313,165)
Cash from financing activities
(1,438,031)
FCF
5,059,702
3,721,715
2,330,006
Balance
Cash
12,132,267
11,624,415
9,926,307
Long term investments
25,432
27,702
169,847
Excess cash
11,264,655
10,883,496
9,365,999
Stockholders' equity
17,052,504
16,630,984
14,862,120
Invested Capital
11,748,071
10,193,632
10,536,501
ROIC
55.69%
32.90%
32.66%
ROCE
28.70%
18.63%
18.70%
EV
Common stock shares outstanding
1,371,470
1,370,973
1,371,366
Price
53.70
20.19%
44.68
-0.67%
44.98
88.20%
Market cap
73,647,953
20.23%
61,255,065
-0.70%
61,684,056
88.17%
EV
72,343,617
59,988,502
61,999,303
EBITDA
7,522,632
4,813,316
4,550,431
EV/EBITDA
9.62
12.46
13.62
Interest
119,676
111,398
127,352
Interest/NOPBT
1.81%
2.84%
3.42%